Hepatitis C Therapeutics in Major Developed Markets to 2019 : Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape
Reportstack, provider of premium market research reports announces the addition of Hepatitis C Therapeutics in Major Developed Markets to 2019 : Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape market report to its offering
The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial...
View full press release